Healthy By Nature
- Vitamin IV Therapy
- IV Therapy
- Chelation Therapy
- Red Light Therapy
- Hormone Replacement Therapy (HRT)
Los Angeles, CA
Chelation therapy in Los Angeles is offered by a small set of integrative and naturopathic clinics, typically for documented heavy metal toxicity. Referral and testing pathways often interact with Cedars-Sinai, UCLA Health, Kaiser Permanente, and Keck Medicine of USC when lab confirmation is needed. Local demand is shaped by an entertainment-industry and aesthetically motivated patient base, and clinics vary in whether they push short detox courses or longer TACT-modeled cardiovascular protocols.
FDA-approved agents for specific poisoning diagnoses include calcium disodium EDTA, DMSA, and deferoxamine. Chelation for cardiovascular disease or autism is not FDA-approved and has caused deaths when the wrong EDTA form is used. California Medical Board scrutiny of medspas, NP corporations, and stem cell claims shapes which providers can deliver chelation and under what supervision.
With verified chelation clinics on Regenerated.com in Los Angeles, California, patients can compare provider credentials, testing protocols, and whether the clinic uses calcium disodium EDTA (the correct form) or the dangerous disodium EDTA. ACAM-trained MDs with documented pre-treatment heavy metal testing are the minimum bar.
Regulatory context
The FDA has approved a narrow set of chelating agents for specific heavy metal toxicities. Calcium disodium edetate (CaNa2EDTA, Versenate) is approved for symptomatic lead poisoning, succimer (Chemet, DMSA) for pediatric lead poisoning at blood lead levels above 45 mcg/dL, deferoxamine (Desferal) and deferasirox (Exjade) for chronic iron overload, and dimercaprol (BAL) for arsenic, gold, and acute lead poisoning. Use of EDTA chelation for cardiovascular disease was studied in the NIH-funded TACT trial (2013) with controversial findings and remains not FDA-approved for that indication. Chelation for autism spectrum disorder is not evidence-based and has been linked to pediatric deaths. The FDA issued a 2010 sweep of warning letters to compounders marketing OTC chelation products with unapproved disease claims.
The Medical Board of California has disciplined physicians for marketing chelation as a treatment for autism, atherosclerosis, and Alzheimer's disease without adequate informed consent or evidence base. California Department of Public Health has investigated clinics for unsanitary IV practices. The Pittsburgh 2005 pediatric autism chelation death prompted California medical board guidance reinforcing that the wrong EDTA salt (Na2EDTA versus CaNa2EDTA) can be fatal. Compounded DMPS distribution has drawn scrutiny under California pharmacy law.